Insurance-routed · Programme guide
Medicare GLP-1 Bridge Program: the $50 copay, and who actually qualifies
Medicare now pays for a GLP-1 prescribed purely for weight loss — $50 a month for Wegovy, Foundayo or the Zepbound KwikPen, through the end of 2027. Most guides describe the eligibility rules backwards, and the mistake is expensive in both directions.
Published · Programme terms as published by CMS · Found’s rates as published on that date · Editorial score 9.1 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
For three years the entire cash-pay GLP-1 industry has existed because of one sentence in federal law: Medicare Part D is barred from covering a drug used for weight reduction. That is why every provider in our weight loss rankings is priced as though insurance will say no, and why compounded semaglutide became a market at all.
The Bridge does not repeal that exclusion. It steps around it. CMS built a separate demonstration that sits outside the Part D benefit entirely, pays pharmacies directly, and charges the beneficiary a flat $50 for a monthly supply — for the express purpose, in the agency’s own framing, of increasing access for people who want the drug solely to lose excess weight. That is a reversal, not a loophole, and it is the single biggest change to GLP-1 economics since the drugs launched.
The short answer
- The price
- $50 a month, flat. No deductible applies, so it is $50 from the first fill — against roughly $650 for the same branded medication bought in cash and up to $1,100 at retail.
- The rule everyone gets wrong
- Sleep apnea disqualifies you. So does type 2 diabetes, and so does MASH. The Bridge is for weight reduction on its own. Guides telling you to qualify through an OSA or cardiovascular indication are describing ordinary Part D, not this programme.
- The deadline
- 31 December 2027. The demonstration runs 18 months from 1 July 2026. What replaces it has been postponed indefinitely, so this is a window rather than a new entitlement.
What the Medicare GLP-1 Bridge Program actually is
It is a nationwide Medicare demonstration, live across every state and territory from 1 July 2026 to 31 December 2027. Rather than adding weight-loss drugs to Part D formularies, CMS placed them alongside the benefit: Part D sponsors carry no risk, the plan’s deductible never applies, and the pharmacy is reimbursed at wholesale acquisition cost less your copay. You pay $50 a month and nothing else for the medication.
Three products are in scope, and the detail matters more than the headline. All formulations of Wegovy®, including the tablets. All formulations of Foundayo®. And the KwikPen® formulation of Zepbound® only — not the single-dose vials or pens many people are already using. CMS publishes the covered NDC numbers on its pharmacy guidance for the Bridge, which is the document to check if your pharmacist tells you a product is not eligible.
You cannot run the same drug through Part D at the same time. The Bridge replaces that route rather than supplementing it, which is why the enrolment question is binary and why an existing prescription usually has to be rewritten rather than simply transferred.
Medicare GLP-1 Bridge eligibility: the rules, in the order they disqualify people
You must be 18 or over and enrolled in an eligible drug plan — a standalone Part D plan, a Medicare Advantage plan with drug coverage, a special needs plan, an employer group plan or LI NET all count. There is no upper age limit in the programme itself, which is worth stating plainly because several write-ups quote a 65-to-75 band that comes from one telehealth platform’s own service rules rather than from CMS.
Then the clinical criteria, assessed at the point GLP-1 treatment begins:
- BMI of 35 or above, with no additional condition required
- BMI of 30 or above, plus chronic kidney disease at stage 3a or worse, heart failure with preserved ejection fraction, or high blood pressure still uncontrolled on two medications
- BMI of 27 or above, plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease
The disqualifiers are the part to read twice. Type 2 diabetes, obstructive sleep apnea and MASH each rule you out of the Bridge — because a GLP-1 prescribed for any of those already has a route through ordinary Part D coverage. If you have been told to pursue a sleep apnea diagnosis to unlock the $50 copay, you have been given advice that will get your application denied.
AARP’s breakdown of the $50 copay programme puts the eligible population at roughly 3.8 million beneficiaries. That is a large group by any measure, and a great many of them are currently paying cash for a compounded preparation because they were told Medicare does not cover weight loss — a statement that was true until 1 July and is now, for these three drugs, wrong.
What $50 a month buys, and what it quietly costs
The saving is not subtle. Branded Zepbound or Wegovy bought without coverage runs around $650 a month, and retail pricing on the class reaches $1,100. At $50 flat, with no deductible phase to work through first, the Bridge is roughly a thirteenth of the cash price for an identical, FDA-approved, manufacturer-produced product.
The accounting catch is real but narrow. Because the drugs sit outside the Part D benefit, your $50 payments do not count toward true out-of-pocket costs, so they never move you toward the $2,100 Part D cap for 2026. Low-income subsidy cost-sharing assistance cannot be applied to them, and they are not eligible for the Medicare Prescription Payment Plan that lets you spread drug costs across the year.
For most people that trade is obviously worth taking — $50 that does not count toward a cap beats $650 that also does not count toward a cap. It bites hardest on beneficiaries with high total drug spend who would otherwise hit the cap and then pay nothing, and on those receiving the low-income subsidy, for whom the Bridge copay is one of the few charges their assistance cannot touch.
| Route | Per month | Per year | What you receive |
|---|---|---|---|
| Medicare Bridge, self-managed | $50 | $600 | Branded Wegovy, Foundayo or Zepbound KwikPen, if your own prescriber files it |
| Medicare Bridge via Found | $99 | $1,188 | The same medication, plus clinician care and the paperwork handled |
| Branded, paid in cash | ~$650 | ~$7,800 | The same branded medication with no coverage applied |
Where Found fits, and what it charges
Found is a telehealth weight care platform — it reports more than 300,000 members, 1.4 million pounds lost and a 4.89 average rating — and it has built an intake specifically around the Bridge for adults aged 65 to 75. That age band is Found’s own service window, narrower than the programme’s. Its offer is membership from $49 a month on annual billing, stacked on top of Medicare’s $50, for an advertised total of $99 a month.
What that $49 buys is the administrative work and the clinical care around the prescription. Prior authorisation for the Bridge goes to Humana, which processes claims for the demonstration, against a CMS target of 72 hours; subsequent refills skip authorisation entirely unless the medication changes. Found files and tracks that submission, verifies your plan before you pay anything, and puts a board-certified clinician on the case within one to two days. Monthly check-ins, in-app side-effect support and messaging run for as long as you are a member.
Found also publishes its clinicians by name with individual patient ratings — Dr Molly Middleton at 4.93, Dr Jennifer Wetherington at 4.91, Kai Lehardi NP at 4.87, Gem Escamilla NP at 4.85 — which is a small accountability signal that is easy to copy and revealing that so few platforms bother. On outcomes it reports about 12% average body weight loss at one year across 1,773 tracked users, with 83% sustaining results at a year. That sits below the 15–20% ceiling from the pivotal trials, and Found says so rather than quoting the trial figure, which is the more trustworthy choice. Our full Found review covers the rest of the platform, including the price it declines to publish for its non-Medicare program.
The honest framing is this: the $50 is Medicare’s, not Found’s. If you already have a prescriber willing to handle the authorisation, you can reach the same copay for nothing extra. The membership is worth paying when you do not — and prior authorisation is a genuine deterrent, opaque enough that plenty of people who would qualify never find out because the first denial ends the attempt.
What the Bridge gets right
- Flat $50 copay from the first fill, with no deductible phase to clear
- Branded, FDA-approved medication rather than a compounded preparation
- Weight reduction alone is a qualifying reason — no proxy diagnosis needed
- Nationwide, across every Part D plan type including Medicare Advantage and LI NET
- CMS targets 72-hour prior authorisation, and refills skip it entirely
- Around $6,612 a year cheaper than buying the same drugs in cash, even paying Found's membership
Where it falls short
- Ends 31 December 2027, with no confirmed successor programme
- Type 2 diabetes, obstructive sleep apnea and MASH all disqualify you
- Copays do not count toward true out-of-pocket costs or the $2,100 Part D cap
- Low-income subsidy assistance cannot be applied to Bridge copays
- Only the Zepbound KwikPen is covered, not vials or single-dose pens
- Found's $49 membership rate requires a 12-month billing commitment
How to get the $50 copay, step by step
- Confirm your plan type — a standalone Part D plan, an MA plan with drug coverage, an SNP, an employer group plan or LI NET all qualify
- Check your BMI against the three tiers, using the figure at the point treatment begins rather than today
- Rule out the disqualifiers before you apply: type 2 diabetes, obstructive sleep apnea and MASH each end the application
- Have a prescriber submit the prior authorisation to Humana, which processes claims for the demonstration
- Expect a decision against a 72-hour CMS target; a denial at this stage is usually a documentation problem, not a clinical one
- Fill at a participating pharmacy and pay the flat $50 — refills after the first skip authorisation unless the drug changes
Found compresses the first four of those into a three-minute assessment, a clinician review inside one to two days, and a filing its team tracks on your behalf. The check is free, carries no commitment, and Found verifies your coverage before taking payment — which is the right structure for a programme where eligibility is the entire question.
Who should use it, and who should not
The clearest fit is a Medicare beneficiary with a BMI of 35 or more, no diabetes diagnosis, and a cash quote from a pharmacy counter they have already decided they cannot pay. For that person the Bridge is not a close call: $50 a month for the branded drug, for the next seventeen months, against roughly $650 for the identical product.
It is also worth a second look from anyone who applied for GLP-1 coverage before July 2026 and was refused. That refusal was almost certainly correct under the old rules and tells you nothing about the Bridge, which did not exist when it was issued.
Skip it in three cases. If you have type 2 diabetes, obstructive sleep apnea or MASH, the Bridge is closed to you — but ordinary Part D coverage for a GLP-1 prescribed against that diagnosis is not, and that is the conversation to have with your prescriber instead. If you have no Medicare drug coverage at all, none of this applies. And if your BMI sits below the tiers, a cash-pay compounded programme will treat you faster: altRx at $89 a month or TrimRx at $149 with a lifetime price lock are the two published rates we would start from, at the cost of taking a preparation the FDA has not reviewed for safety, quality or efficacy.
The verdict
The Bridge is the most consequential thing to happen to GLP-1 pricing since the drugs launched, and it is being described inaccurately almost everywhere. The programme does not require you to disguise weight loss as something else. It requires the opposite — the conditions people are told to chase are the ones that shut the door.
Its real weakness is the calendar. Eighteen months of $50 pricing, an indefinitely postponed successor, and a cohort of beneficiaries who will reach 31 December 2027 on a medication that regain follows if you stop. That is worth planning for at the start rather than discovering at the end.
Found is a good route in if you want the filing and the clinical care handled, at $99 a month all-in — roughly $6,612 a year below the cash price, for the branded drug. Run the free eligibility check first, confirm the membership billing term before you commit, and remember that the $50 belongs to Medicare and follows you wherever your prescription is written.
Medicare GLP-1 Bridge: common questions
What is the Medicare GLP-1 Bridge Program?
A time-limited Medicare demonstration running from 1 July 2026 through 31 December 2027, nationwide. Eligible Part D beneficiaries pay a flat $50 copay per monthly supply of Wegovy, Foundayo or the Zepbound KwikPen when the drug is prescribed for weight management. It sits outside the ordinary Part D benefit rather than inside it, which is why it is called a bridge.
Do I need a heart condition or sleep apnea diagnosis to qualify?
No, and sleep apnea specifically works against you. CMS designed the Bridge for beneficiaries seeking a GLP-1 solely to reduce excess body weight, and obstructive sleep apnea, type 2 diabetes and MASH are named as disqualifying conditions. Guides that tell you to route through a cardiovascular or OSA indication are describing ordinary Part D coverage, not this programme.
What are the BMI requirements?
Measured when GLP-1 treatment begins: a BMI of 35 or above on its own; or 30 or above alongside stage 3a or worse chronic kidney disease, heart failure with preserved ejection fraction, or high blood pressure still uncontrolled on two medications; or 27 or above alongside prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
Does the $50 count toward my Part D deductible or out-of-pocket cap?
No to both. The deductible does not apply, so the copay is $50 from the first fill, but the payments also do not count toward true out-of-pocket costs or the $2,100 Part D cap for 2026. Low-income subsidy cost-sharing help cannot be applied to Bridge copays, and the drugs are not eligible for the Medicare Prescription Payment Plan.
Is every form of Zepbound covered?
No. CMS lists all formulations of Wegovy and all formulations of Foundayo, but only the KwikPen formulation of Zepbound. If you are currently on Zepbound single-dose vials or pens, moving to the Bridge means moving to the KwikPen.
What does Found charge on top of the copay?
Membership from $49 a month when billed annually, which brings the advertised total to $99 a month, or $1,188 across a year. The membership buys clinician review, monthly check-ins, in-app side-effect support and messaging, plus the prior authorisation filing. The $50 copay itself is Medicare's price, not Found's.
Do I need a telehealth platform to use the Bridge?
No. The Bridge is a Medicare programme, and any prescriber can submit the prior authorisation to Humana, which processes claims for the demonstration. What you are buying from a platform such as Found is that the paperwork gets filed correctly and tracked, plus ongoing titration care — not access to the $50 rate itself.
How long does approval take?
CMS targets a 72-hour turnaround on the prior authorisation, and later prescriptions skip the authorisation entirely unless the medication changes. Found quotes one to two days for its own clinician review before that, so the two steps run in sequence rather than in parallel.
What happens when the programme ends in 2027?
That is unresolved. CMS indefinitely postponed the pilot the Bridge was originally meant to lead into, extended the Bridge itself by a year, and is collecting usage data from it to inform whatever comes next. Treat the $50 copay as available through 31 December 2027 and nothing beyond that as settled.
Is Found the only way to get the Bridge copay?
No, and it is worth being clear about that. Found does the administrative work and provides the clinical care, but the copay is set by Medicare and is the same wherever your prescription originates. If you already have a prescriber willing to file the authorisation, you do not need to pay a membership fee to reach the same $50.
Keep comparing
See how the rest of the market prices the same treatment on the weight loss rankings, or read the head-to-head articles in the comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Programme terms describe the Medicare GLP-1 Bridge demonstration as published by CMS and summarised by AARP on the date above; the demonstration is scheduled to end on 31 December 2027 and its terms can change. Eligibility is determined by Medicare and your prescriber, not by eRxDoctor. Found's $49 membership rate reflects annual billing and is separate from the $50 Medicare copay. The cash branded comparison is an approximate market rate rather than a Found quote.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Found, and does not sell treatment. Read our ranking methodology.